Assertio Holdings, Inc. (NASDAQ: ASRT) Stock Competitors & Peer Comparison
See ASRT's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ASRT and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ASRT | $23.50 | +0.00% | 151.9M | -7.10 | -$3.31 | N/A |
| TAK | $17.42 | -0.37% | 55.4B | 12.52 | $1.39 | +3.62% |
| HLN | $9.79 | -1.51% | 43.2B | 18.28 | $0.54 | +1.80% |
| TEVA | $37.04 | +1.54% | 42.8B | 12.54 | $2.93 | N/A |
| VTRS | $16.25 | -0.16% | 18.7B | 6.39 | $2.52 | +2.98% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| ELAN | $22.60 | -0.59% | 11.1B | 20.91 | $1.06 | N/A |
| RDY | $12.42 | -0.24% | 10.3B | 20.30 | $0.61 | +0.67% |
| LNTH | $100.90 | +0.22% | 6.6B | 16.93 | $5.95 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
ASRT vs TAK Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, TAK has a market cap of 55.4B. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while TAK trades at $17.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas TAK's P/E ratio is 12.52. In terms of profitability, ASRT's ROE is -0.39%, compared to TAK's ROE of +0.02%. Regarding short-term risk, ASRT is less volatile compared to TAK. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check TAK's competition here
Haleon plc (NYSE: HLN)
ASRT vs HLN Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, HLN has a market cap of 43.2B. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while HLN trades at $9.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas HLN's P/E ratio is 18.28. In terms of profitability, ASRT's ROE is -0.39%, compared to HLN's ROE of +0.17%. Regarding short-term risk, ASRT is less volatile compared to HLN. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
ASRT vs TEVA Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, TEVA has a market cap of 42.8B. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while TEVA trades at $37.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas TEVA's P/E ratio is 12.54. In terms of profitability, ASRT's ROE is -0.39%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, ASRT is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check TEVA's competition here
Viatris Inc. (NASDAQ: VTRS)
ASRT vs VTRS Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, VTRS has a market cap of 18.7B. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while VTRS trades at $16.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas VTRS's P/E ratio is 6.39. In terms of profitability, ASRT's ROE is -0.39%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, ASRT is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
ASRT vs ITCI Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas ITCI's P/E ratio is -180.64. In terms of profitability, ASRT's ROE is -0.39%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, ASRT is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for ASRT.Check ITCI's competition here
Catalent, Inc. (NYSE: CTLT)
ASRT vs CTLT Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas CTLT's P/E ratio is -27.84. In terms of profitability, ASRT's ROE is -0.39%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, ASRT is similarly volatile compared to CTLT. This indicates similar risk in terms of short-term price fluctuations for ASRT.Check CTLT's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
ASRT vs ELAN Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, ELAN has a market cap of 11.1B. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while ELAN trades at $22.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas ELAN's P/E ratio is 20.91. In terms of profitability, ASRT's ROE is -0.39%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, ASRT is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
ASRT vs RDY Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, RDY has a market cap of 10.3B. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while RDY trades at $12.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas RDY's P/E ratio is 20.30. In terms of profitability, ASRT's ROE is -0.39%, compared to RDY's ROE of +0.09%. Regarding short-term risk, ASRT is less volatile compared to RDY. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check RDY's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
ASRT vs LNTH Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while LNTH trades at $100.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas LNTH's P/E ratio is 16.93. In terms of profitability, ASRT's ROE is -0.39%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, ASRT is less volatile compared to LNTH. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
ASRT vs AMRX Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, AMRX has a market cap of 5.6B. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while AMRX trades at $17.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas AMRX's P/E ratio is 19.62. In terms of profitability, ASRT's ROE is -0.39%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, ASRT is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
ASRT vs INDV Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, INDV has a market cap of 4.8B. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while INDV trades at $38.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas INDV's P/E ratio is 10.61. In terms of profitability, ASRT's ROE is -0.39%, compared to INDV's ROE of -2.16%. Regarding short-term risk, ASRT is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check INDV's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
ASRT vs SUPN Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, SUPN has a market cap of 2.8B. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while SUPN trades at $47.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas SUPN's P/E ratio is 15.64. In terms of profitability, ASRT's ROE is -0.39%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, ASRT is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check SUPN's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
ASRT vs RGC Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, RGC has a market cap of 2.5B. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while RGC trades at $5.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas RGC's P/E ratio is -356.34. In terms of profitability, ASRT's ROE is -0.39%, compared to RGC's ROE of -2.32%. Regarding short-term risk, ASRT is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check RGC's competition here
Bausch Health Companies Inc. (NYSE: BHC)
ASRT vs BHC Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, BHC has a market cap of 2.3B. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while BHC trades at $6.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas BHC's P/E ratio is 1.58. In terms of profitability, ASRT's ROE is -0.39%, compared to BHC's ROE of +0.89%. Regarding short-term risk, ASRT is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check BHC's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
ASRT vs DCPH Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas DCPH's P/E ratio is -11.58. In terms of profitability, ASRT's ROE is -0.39%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, ASRT is less volatile compared to DCPH. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check DCPH's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
ASRT vs HCM Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, HCM has a market cap of 2.1B. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while HCM trades at $12.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas HCM's P/E ratio is 4.59. In terms of profitability, ASRT's ROE is -0.39%, compared to HCM's ROE of +0.01%. Regarding short-term risk, ASRT is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check HCM's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
ASRT vs AVDL Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, ASRT's ROE is -0.39%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, ASRT is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for ASRT.Check AVDL's competition here
Embecta Corp. (NASDAQ: EMBCV)
ASRT vs EMBCV Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas EMBCV's P/E ratio is N/A. In terms of profitability, ASRT's ROE is -0.39%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, ASRT is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
ASRT vs DVAX Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas DVAX's P/E ratio is -41.89. In terms of profitability, ASRT's ROE is -0.39%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, ASRT is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for ASRT.Check DVAX's competition here
Perrigo Company plc (NYSE: PRGO)
ASRT vs PRGO Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, PRGO has a market cap of 1.8B. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while PRGO trades at $12.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas PRGO's P/E ratio is 5.07. In terms of profitability, ASRT's ROE is -0.39%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, ASRT is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check PRGO's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
ASRT vs ANIP Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while ANIP trades at $75.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas ANIP's P/E ratio is 9.14. In terms of profitability, ASRT's ROE is -0.39%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, ASRT is less volatile compared to ANIP. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
ASRT vs TARO Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas TARO's P/E ratio is 30.05. In terms of profitability, ASRT's ROE is -0.39%, compared to TARO's ROE of +0.03%. Regarding short-term risk, ASRT is similarly volatile compared to TARO. This indicates similar risk in terms of short-term price fluctuations for ASRT.Check TARO's competition here
Harrow Health, Inc. (NASDAQ: HROW)
ASRT vs HROW Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, HROW has a market cap of 1.5B. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while HROW trades at $39.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas HROW's P/E ratio is 437.33. In terms of profitability, ASRT's ROE is -0.39%, compared to HROW's ROE of -1.04%. Regarding short-term risk, ASRT is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check HROW's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
ASRT vs PAHC Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while PAHC trades at $34.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas PAHC's P/E ratio is 11.54. In terms of profitability, ASRT's ROE is -0.39%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, ASRT is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check PAHC's competition here
Alvotech (NASDAQ: ALVO)
ASRT vs ALVO Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, ALVO has a market cap of 1.4B. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while ALVO trades at $3.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas ALVO's P/E ratio is -11.79. In terms of profitability, ASRT's ROE is -0.39%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, ASRT is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check ALVO's competition here
Cronos Group Inc. (NASDAQ: CRON)
ASRT vs CRON Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while CRON trades at $3.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas CRON's P/E ratio is 30.10. In terms of profitability, ASRT's ROE is -0.39%, compared to CRON's ROE of +0.06%. Regarding short-term risk, ASRT is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check CRON's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
ASRT vs ETON Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, ETON has a market cap of 1.1B. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while ETON trades at $42.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas ETON's P/E ratio is -594.00. In terms of profitability, ASRT's ROE is -0.39%, compared to ETON's ROE of -0.06%. Regarding short-term risk, ASRT is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check ETON's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
ASRT vs PCRX Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, PCRX has a market cap of 932.2M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while PCRX trades at $23.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas PCRX's P/E ratio is 9.12. In terms of profitability, ASRT's ROE is -0.39%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, ASRT is less volatile compared to PCRX. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check PCRX's competition here
PetIQ, Inc. (NASDAQ: PETQ)
ASRT vs PETQ Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas PETQ's P/E ratio is 83.73. In terms of profitability, ASRT's ROE is -0.39%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, ASRT is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for ASRT.Check PETQ's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
ASRT vs AMPH Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, AMPH has a market cap of 881M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while AMPH trades at $20.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas AMPH's P/E ratio is 6.82. In terms of profitability, ASRT's ROE is -0.39%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, ASRT is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check AMPH's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
ASRT vs COLL Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, COLL has a market cap of 842.6M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while COLL trades at $28.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas COLL's P/E ratio is 3.26. In terms of profitability, ASRT's ROE is -0.39%, compared to COLL's ROE of +0.16%. Regarding short-term risk, ASRT is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check COLL's competition here
Evotec SE (NASDAQ: EVO)
ASRT vs EVO Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, EVO has a market cap of 778M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while EVO trades at $2.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas EVO's P/E ratio is -3.09. In terms of profitability, ASRT's ROE is -0.39%, compared to EVO's ROE of -0.24%. Regarding short-term risk, ASRT is less volatile compared to EVO. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check EVO's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
ASRT vs IRWD Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, IRWD has a market cap of 711.1M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while IRWD trades at $4.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas IRWD's P/E ratio is 5.54. In terms of profitability, ASRT's ROE is -0.39%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, ASRT is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check IRWD's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
ASRT vs BDSI Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas BDSI's P/E ratio is 6.82. In terms of profitability, ASRT's ROE is -0.39%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, ASRT is less volatile compared to BDSI. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check BDSI's competition here
Evolus, Inc. (NASDAQ: EOLS)
ASRT vs EOLS Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, EOLS has a market cap of 534.7M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while EOLS trades at $8.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas EOLS's P/E ratio is -25.71. In terms of profitability, ASRT's ROE is -0.39%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, ASRT is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check EOLS's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
ASRT vs AQST Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, AQST has a market cap of 530.7M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while AQST trades at $4.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas AQST's P/E ratio is -6.93. In terms of profitability, ASRT's ROE is -0.39%, compared to AQST's ROE of +2.44%. Regarding short-term risk, ASRT is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check AQST's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
ASRT vs TLRY Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, TLRY has a market cap of 523.4M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while TLRY trades at $4.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas TLRY's P/E ratio is -4.32. In terms of profitability, ASRT's ROE is -0.39%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, ASRT is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check TLRY's competition here
Canopy Growth Corporation (NASDAQ: CGC)
ASRT vs CGC Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, CGC has a market cap of 432.7M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while CGC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas CGC's P/E ratio is -0.62. In terms of profitability, ASRT's ROE is -0.39%, compared to CGC's ROE of -0.33%. Regarding short-term risk, ASRT is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check CGC's competition here
Kamada Ltd. (NASDAQ: KMDA)
ASRT vs KMDA Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, KMDA has a market cap of 396.9M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while KMDA trades at $7.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas KMDA's P/E ratio is 19.66. In terms of profitability, ASRT's ROE is -0.39%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, ASRT is less volatile compared to KMDA. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check KMDA's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
ASRT vs TKNO Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, TKNO has a market cap of 396.2M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while TKNO trades at $7.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas TKNO's P/E ratio is -23.84. In terms of profitability, ASRT's ROE is -0.39%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, ASRT is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check TKNO's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
ASRT vs ALIM Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas ALIM's P/E ratio is 5.28. In terms of profitability, ASRT's ROE is -0.39%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, ASRT is less volatile compared to ALIM. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check ALIM's competition here
Embecta Corp. (NASDAQ: EMBC)
ASRT vs EMBC Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, EMBC has a market cap of 281.8M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while EMBC trades at $5.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas EMBC's P/E ratio is 1.83. In terms of profitability, ASRT's ROE is -0.39%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, ASRT is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check EMBC's competition here
Landec Corporation (NASDAQ: LNDC)
ASRT vs LNDC Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas LNDC's P/E ratio is -4.04. In terms of profitability, ASRT's ROE is -0.39%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, ASRT is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
ASRT vs ACB Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, ACB has a market cap of 236.6M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while ACB trades at $3.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas ACB's P/E ratio is -7.80. In terms of profitability, ASRT's ROE is -0.39%, compared to ACB's ROE of -0.21%. Regarding short-term risk, ASRT is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check ACB's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
ASRT vs ORGO Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, ORGO has a market cap of 232.9M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while ORGO trades at $1.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas ORGO's P/E ratio is 60.33. In terms of profitability, ASRT's ROE is -0.39%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, ASRT is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check ORGO's competition here
Shineco, Inc. (NASDAQ: TYHT)
ASRT vs TYHT Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas TYHT's P/E ratio is -1.61. In terms of profitability, ASRT's ROE is -0.39%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, ASRT is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
ASRT vs SIGA Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, SIGA has a market cap of 205.8M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while SIGA trades at $2.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas SIGA's P/E ratio is 10.63. In terms of profitability, ASRT's ROE is -0.39%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, ASRT is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check SIGA's competition here
Organigram Global Inc. (NASDAQ: OGI)
ASRT vs OGI Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, OGI has a market cap of 181.6M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while OGI trades at $1.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas OGI's P/E ratio is -4.96. In terms of profitability, ASRT's ROE is -0.39%, compared to OGI's ROE of -0.07%. Regarding short-term risk, ASRT is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check OGI's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
ASRT vs LFCR Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, LFCR has a market cap of 178.9M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while LFCR trades at $4.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas LFCR's P/E ratio is -4.46. In terms of profitability, ASRT's ROE is -0.39%, compared to LFCR's ROE of -2.51%. Regarding short-term risk, ASRT is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check LFCR's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
ASRT vs REPH Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas REPH's P/E ratio is -8.04. In terms of profitability, ASRT's ROE is -0.39%, compared to REPH's ROE of -0.22%. Regarding short-term risk, ASRT is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check REPH's competition here
Journey Medical Corporation (NASDAQ: DERM)
ASRT vs DERM Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, DERM has a market cap of 177M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while DERM trades at $6.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas DERM's P/E ratio is -17.38. In terms of profitability, ASRT's ROE is -0.39%, compared to DERM's ROE of -0.36%. Regarding short-term risk, ASRT is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check DERM's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
ASRT vs CRDL Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, CRDL has a market cap of 175.2M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while CRDL trades at $1.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas CRDL's P/E ratio is -5.41. In terms of profitability, ASRT's ROE is -0.39%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, ASRT is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check CRDL's competition here
Theratechnologies Inc. (NASDAQ: THTX)
ASRT vs THTX Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas THTX's P/E ratio is -28.83. In terms of profitability, ASRT's ROE is -0.39%, compared to THTX's ROE of +0.17%. Regarding short-term risk, ASRT is less volatile compared to THTX. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check THTX's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
ASRT vs CPIX Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, CPIX has a market cap of 119.3M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while CPIX trades at $7.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas CPIX's P/E ratio is -19.90. In terms of profitability, ASRT's ROE is -0.39%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, ASRT is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check CPIX's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
ASRT vs SCTL Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas SCTL's P/E ratio is -7.86. In terms of profitability, ASRT's ROE is -0.39%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, ASRT is less volatile compared to SCTL. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
ASRT vs BGM Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, BGM has a market cap of 111.9M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while BGM trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas BGM's P/E ratio is -1.01. In terms of profitability, ASRT's ROE is -0.39%, compared to BGM's ROE of -0.07%. Regarding short-term risk, ASRT is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check BGM's competition here
Procaps Group S.A. (NASDAQ: PROC)
ASRT vs PROC Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas PROC's P/E ratio is 1.53. In terms of profitability, ASRT's ROE is -0.39%, compared to PROC's ROE of -2.22%. Regarding short-term risk, ASRT is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for ASRT.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
ASRT vs OPTN Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas OPTN's P/E ratio is -4.42. In terms of profitability, ASRT's ROE is -0.39%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, ASRT is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for ASRT.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
ASRT vs ZOM Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas ZOM's P/E ratio is -1.62. In terms of profitability, ASRT's ROE is -0.39%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, ASRT is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
ASRT vs GRVI Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas GRVI's P/E ratio is 26.05. In terms of profitability, ASRT's ROE is -0.39%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, ASRT is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check GRVI's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
ASRT vs ZYBT Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, ZYBT has a market cap of 73.5M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while ZYBT trades at $1.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas ZYBT's P/E ratio is -7.05. In terms of profitability, ASRT's ROE is -0.39%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, ASRT is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check ZYBT's competition here
Talphera, Inc. (NASDAQ: TLPH)
ASRT vs TLPH Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, TLPH has a market cap of 72.7M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while TLPH trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas TLPH's P/E ratio is -4.52. In terms of profitability, ASRT's ROE is -0.39%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, ASRT is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check TLPH's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
ASRT vs ZYNE Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, ASRT's ROE is -0.39%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, ASRT is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
ASRT vs SSIC Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas SSIC's P/E ratio is 11.93. In terms of profitability, ASRT's ROE is -0.39%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, ASRT is less volatile compared to SSIC. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
ASRT vs VLNS Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas VLNS's P/E ratio is -1.03. In terms of profitability, ASRT's ROE is -0.39%, compared to VLNS's ROE of N/A. Regarding short-term risk, ASRT is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
ASRT vs DRRX Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas DRRX's P/E ratio is -4.44. In terms of profitability, ASRT's ROE is -0.39%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, ASRT is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for ASRT.Check DRRX's competition here
InterCure Ltd. (NASDAQ: INCR)
ASRT vs INCR Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, INCR has a market cap of 57.1M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while INCR trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas INCR's P/E ratio is -2.23. In terms of profitability, ASRT's ROE is -0.39%, compared to INCR's ROE of -0.09%. Regarding short-term risk, ASRT is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
ASRT vs JUPW Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas JUPW's P/E ratio is -2.41. In terms of profitability, ASRT's ROE is -0.39%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, ASRT is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check JUPW's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
ASRT vs CPHI Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, CPHI has a market cap of 44.6M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while CPHI trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas CPHI's P/E ratio is -1.72. In terms of profitability, ASRT's ROE is -0.39%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, ASRT is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check CPHI's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
ASRT vs QLI Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas QLI's P/E ratio is -4.92. In terms of profitability, ASRT's ROE is -0.39%, compared to QLI's ROE of -0.16%. Regarding short-term risk, ASRT is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for ASRT.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
ASRT vs HEXO Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas HEXO's P/E ratio is -0.26. In terms of profitability, ASRT's ROE is -0.39%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, ASRT is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check HEXO's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
ASRT vs RMTI Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, RMTI has a market cap of 30.8M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while RMTI trades at $7.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas RMTI's P/E ratio is -7.42. In terms of profitability, ASRT's ROE is -0.39%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, ASRT is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check RMTI's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
ASRT vs AYTU Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, AYTU has a market cap of 25.3M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while AYTU trades at $2.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas AYTU's P/E ratio is -1.23. In terms of profitability, ASRT's ROE is -0.39%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, ASRT is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check AYTU's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
ASRT vs TXMD Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, TXMD has a market cap of 24.1M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while TXMD trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas TXMD's P/E ratio is 105.96. In terms of profitability, ASRT's ROE is -0.39%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, ASRT is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check TXMD's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
ASRT vs CYTH Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas CYTH's P/E ratio is -0.80. In terms of profitability, ASRT's ROE is -0.39%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, ASRT is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for ASRT.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
ASRT vs EVOK Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas EVOK's P/E ratio is -7.97. In terms of profitability, ASRT's ROE is -0.39%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, ASRT is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for ASRT.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
ASRT vs OPTH Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, OPTH has a market cap of 15.3M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while OPTH trades at $4.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas OPTH's P/E ratio is -17.38. In terms of profitability, ASRT's ROE is -0.39%, compared to OPTH's ROE of -0.94%. Regarding short-term risk, ASRT is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
ASRT vs ACRX Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas ACRX's P/E ratio is -0.31. In terms of profitability, ASRT's ROE is -0.39%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, ASRT is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check ACRX's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
ASRT vs BFRIW Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, BFRIW has a market cap of 13.3M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while BFRIW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas BFRIW's P/E ratio is -0.02. In terms of profitability, ASRT's ROE is -0.39%, compared to BFRIW's ROE of -4.77%. Regarding short-term risk, ASRT is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check BFRIW's competition here
Cosmos Health Inc. (NASDAQ: COSM)
ASRT vs COSM Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, COSM has a market cap of 11.7M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while COSM trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas COSM's P/E ratio is -0.29. In terms of profitability, ASRT's ROE is -0.39%, compared to COSM's ROE of -0.96%. Regarding short-term risk, ASRT is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check COSM's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
ASRT vs AGRX Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas AGRX's P/E ratio is -0.89. In terms of profitability, ASRT's ROE is -0.39%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, ASRT is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
ASRT vs NLTX Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas NLTX's P/E ratio is -0.28. In terms of profitability, ASRT's ROE is -0.39%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, ASRT is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
ASRT vs LCI Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas LCI's P/E ratio is -0.04. In terms of profitability, ASRT's ROE is -0.39%, compared to LCI's ROE of +1.66%. Regarding short-term risk, ASRT is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
ASRT vs ADMP Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas ADMP's P/E ratio is -0.08. In terms of profitability, ASRT's ROE is -0.39%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, ASRT is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
ASRT vs YCBD Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, YCBD has a market cap of 6.3M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while YCBD trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas YCBD's P/E ratio is -1.49. In terms of profitability, ASRT's ROE is -0.39%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, ASRT is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check YCBD's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
ASRT vs GELS Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, GELS has a market cap of 5.2M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while GELS trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas GELS's P/E ratio is -1.14. In terms of profitability, ASRT's ROE is -0.39%, compared to GELS's ROE of -0.25%. Regarding short-term risk, ASRT is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check GELS's competition here
Mallinckrodt plc (AMEX: MNK)
ASRT vs MNK Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas MNK's P/E ratio is -0.44. In terms of profitability, ASRT's ROE is -0.39%, compared to MNK's ROE of -0.36%. Regarding short-term risk, ASRT is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
ASRT vs FLGC Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas FLGC's P/E ratio is -0.19. In terms of profitability, ASRT's ROE is -0.39%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, ASRT is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
ASRT vs UPC Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, UPC has a market cap of 3.8M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while UPC trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas UPC's P/E ratio is -0.75. In terms of profitability, ASRT's ROE is -0.39%, compared to UPC's ROE of -0.03%. Regarding short-term risk, ASRT is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check UPC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
ASRT vs SBFM Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, SBFM has a market cap of 2.9M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while SBFM trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas SBFM's P/E ratio is -0.20. In terms of profitability, ASRT's ROE is -0.39%, compared to SBFM's ROE of -0.26%. Regarding short-term risk, ASRT is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check SBFM's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
ASRT vs PLXP Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas PLXP's P/E ratio is -0.22. In terms of profitability, ASRT's ROE is -0.39%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, ASRT is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check PLXP's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
ASRT vs SHPH Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, SHPH has a market cap of 2.5M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while SHPH trades at $4.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas SHPH's P/E ratio is -0.20. In terms of profitability, ASRT's ROE is -0.39%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, ASRT is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check SHPH's competition here
Athenex, Inc. (NASDAQ: ATNX)
ASRT vs ATNX Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas ATNX's P/E ratio is -0.02. In terms of profitability, ASRT's ROE is -0.39%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, ASRT is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for ASRT.Check ATNX's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
ASRT vs SNOA Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, SNOA has a market cap of 2.3M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while SNOA trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas SNOA's P/E ratio is -1.16. In terms of profitability, ASRT's ROE is -0.39%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, ASRT is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check SNOA's competition here
Procaps Group, S.A. (NASDAQ: PROCW)
ASRT vs PROCW Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas PROCW's P/E ratio is N/A. In terms of profitability, ASRT's ROE is -0.39%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, ASRT is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for ASRT.Check PROCW's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
ASRT vs RDHL Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, RDHL has a market cap of 1.9M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while RDHL trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas RDHL's P/E ratio is 0.12. In terms of profitability, ASRT's ROE is -0.39%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, ASRT is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check RDHL's competition here
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)
ASRT vs SXTC Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, SXTC has a market cap of 1.8M. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while SXTC trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas SXTC's P/E ratio is 1.18. In terms of profitability, ASRT's ROE is -0.39%, compared to SXTC's ROE of -0.31%. Regarding short-term risk, ASRT is less volatile compared to SXTC. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check SXTC's competition here
cbdMD, Inc. (AMEX: YCBD-PA)
ASRT vs YCBD-PA Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, YCBD-PA has a market cap of 928.2K. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while YCBD-PA trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas YCBD-PA's P/E ratio is -2.69. In terms of profitability, ASRT's ROE is -0.39%, compared to YCBD-PA's ROE of -0.34%. Regarding short-term risk, ASRT is less volatile compared to YCBD-PA. This indicates lower risk in terms of short-term price fluctuations for ASRT.Check YCBD-PA's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTHW)
ASRT vs CYTHW Comparison August 2026
Assertio Holdings, Inc. (NASDAQ: ASRT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 151.9M. In comparison, CYTHW has a market cap of 928K. Regarding current trading prices, ASRT is priced at $23.50 on the NASDAQ, while CYTHW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -7.10, whereas CYTHW's P/E ratio is N/A. In terms of profitability, ASRT's ROE is -0.39%, compared to CYTHW's ROE of -7.30%. Regarding short-term risk, ASRT is more volatile compared to CYTHW. This indicates higher risk in terms of short-term price fluctuations for ASRT.Check CYTHW's competition here